The final, formatted version of the article will be published soon.
REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1398109
This article is part of the Research Topic Prostate Cancer Research: Tools, Cancer Cell Types, Molecular Targets View all 4 articles
IMMUNOME PROFILING IN PROSTATE CANCER: A guide for clinicians
Provisionally accepted- 1 Urology Department, Hospital Universitario de La Princesa, Madrid, Spain
- 2 Immunology Department, Hospital Universitario de La Princesa, Madrid, Asturias, Spain
- 3 Personalized Precision Medicine Chair, Universidad Autónoma de Madrid, Madrid, Asturias, Spain
- 4 Medical Oncology Department. Hospital Universitario Clínico San Carlos, Madrid, Asturias, Spain
- 5 Medical Oncology Department. Hospital Universitario 12 de Octubre, Madrid, Asturias, Spain
- 6 Medical Oncology Department. Hospital Universitario de La Princesa, Madrid, Asturias, Spain
- 7 Radiation Oncology Department, Hospital Universitario de La Princesa, Madrid, Asturias, Spain
- 8 Medical Oncology Department. Clínica Universitaria de Navarra, Madrid, Spain
- 9 Biocomputing Unit. Hospital Niño Jesús. Instituto de Investigación Sanitaria de la Princesa, Madrid, Spain
Tumor immune microenvironment (TIME) plays a key role to understand how tumors respond to prostate cancer (PC) therapies and potential mechanisms of resistance. Previous research has suggested that specific genomic aberrations, such as microsatellite instability (MSI) or CDK12 bi-allelic loss can allow PC patients more likely to respond to immune checkpoint inhibitors (ICI) or other immune therapies. However, responses to these treatments remain highly variable even in selected patients. Thus, it is essential to obtain more information about tumor immune cells that infiltrate these tumors, and on their plasticity and interactions, in order to better understand the underlying biology to allow development of new therapeutic strategies. This review analyzes: 1) How interactions among immune cell populations and other cells infiltrating the tumor stroma can modulate the progression of PC, 2) How the standard therapies to treat PC (such as androgen deprivation therapy, new androgen-directed hormone therapy or chemotherapy) may influence the dynamic changes of the immunome and 3) What are the limitations in characterizing the immune landscape of the host´s response to tumors.
Keywords: Immunome, prostate cancer, biomarkers, immunophenotype, Immunotherapy
Received: 08 Mar 2024; Accepted: 28 Oct 2024.
Copyright: © 2024 San Jose, Alfranca, Moreno-Pérez, Ruvic-Vico, Velasco, Toquero, Pacheco, Aldave, Zapatero, Celada, Albers, Fenor de la Maza, García Martínez, Castro, Olmos, Colomer and Romero-Laorden. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Nuria Romero-Laorden, Personalized Precision Medicine Chair, Universidad Autónoma de Madrid, Madrid, Asturias, Spain
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.